Abstract Aims: Detailed data on patients admitted for acute myocardial infarction (AMI) on a European-wide basis are lacking. The Euro Heart Survey 2009 Snapshot was designed to assess characteristics, management, and hospital outcomes of AMI patients throughout European Society of Cardiology (ESC) member countries in a contemporary 'real-world' setting, using a methodology designed to improve the representativeness of the survey. Methods: Member countries of the ESC were invited to participate in a 1-week survey of all patients admitted for documented AMI in December 2009. Data on baseline characteristics, type of AMI, management, and complications were recorded using a dedicated electronic form. In addition, we used data collected during the same time period in national registries in Sweden, England, and Wales. Data were centralized at the European Heart House. Results: Overall, 4236 patients (mean age 66±13 years; 31% women) were included in the study in 47 countries. Sixty per cent of patients had ST-segment elevation myocardial infarction, with 50% having primary percutaneous coronary intervention and 21% fibrinolysis. Aspirin and thienopyridines were used in >90%. Unfractionated and low-molecularweight heparins were the most commonly used anticoagulants. Statins, beta-blockers, and angiotensin-converting enzyme inhibitors were used in >80% of the patients. In-hospital mortality was 6.2%. Regional differences were observed, both in terms of population characteristics, management, and outcomes. Conclusions: In-hospital mortality of patients admitted for AMI in Europe is low. Although regional variations exist in their presentation and management, differences are limited and have only moderate impact on early outcomes.
Introduction
Cardiovascular disease is the leading cause of death worldwide. [1] [2] [3] Among cardiovascular conditions, coronary artery disease is the most prevalent, and myocardial infarction is a major cause of cardiovascular hospitalizations, with high rates of acute complications. The situation has improved in recent decades, with a major decrease in cardiovascular mortality, beginning with Western countries followed additionally by falling mortality in Eastern European countries. This general trend to decreased cardiovascular mortality is observed in countries having initially high cardiovascular disease burden, such as Northern European countries or North America, and in those with initially low cardiovascular disease rates, such as most Mediterranean countries. 2 This remarkable achievement is attributed to both improved primary prevention and improved treatment of established cardiovascular disease. In particular, over the preceding 20 years several major clinical trials have documented the ability of new cardiovascular medications and/or procedures to improve clinical outcomes in patients with acute coronary syndromes (ACS), both with and without ST-segment elevation. The results of these trials have been incorporated in guidelines providing clear practice recommendations for clinicians. 4, 5 Observational data collected from cohorts of patients presenting with ACS give the opportunity to determine whether the guidelines have been implemented and translated into changes in everyday practice. They also permit researchers and clinicians to determine the risk profile and characteristics of patients experiencing an ACS event, according to the countries they inhabit. Finally, they give the opportunity to make a link between different management strategies and clinical outcomes, and to study the characteristics and outcomes of populations which are largely underrepresented in randomized controlled trials, such as patients with significant comorbidities, women, or elderly patients. 6 In the early 2000s, the European Society of Cardiology (ESC) launched the Euro Heart Survey (EHS) programme, which was designed to gather information on the management and outcome of patients presenting with ACS in participating centres from the ESC member countries. The initial surveys provided some of the first multinational estimates of ACS patients' profiles in Europe and brought invaluable information to the cardiology community. However, the design (recruitment over a prolonged period of several months or years) and innovative nature of the initial surveys, in which a limited number of centres participated, precluded use of the data as a true epidemiological tool; thus, the first EHS-ACS survey (2000) (2001) included 103 hospitals from 25 countries, 7 the second (2004) included 190 institutions from 32 countries, 8 and EHS- ACS 3 (2006 ACS 3 ( -2008 included 138 centres from 21 countries. 9 In order to maximize the number of participating institutions and to increase the representativeness of the survey and to explore potential regional variations in baseline characteristics and management of patients admitted with acute myocardial infarction (AMI), the EHS developed a so-called snapshot design with a brief, 1-week, inclusion period,
Aims of the survey
The main objectives of the survey were to assess characteristics, management, and hospital outcomes of patients presenting with ACS throughout ESC member countries. Secondary objectives were to describe in-hospital outcomes according to initial management and assess how current guidelines were implemented in a contemporary setting.
Methods

Inclusion criteria
The EHS 2009 AMI snapshot is a prospective, multicentre observational study, including consecutive adult (≥18 years) men and women admitted with a diagnosis of AMI from 7 to 13 December 2009 at participating institutions in 47 countries.
The following inclusion criteria were used:
• acute myocardial infarction (AMI), defined by elevated cardiac markers (troponin, CK, CK-MB), and one or more of the following characteristics: symptoms compatible with myocardial ischaemia, development of new Q waves, or development of ST-T abnormalities considered of ischaemic origin • AMI occurring spontaneously or after non-cardiac procedures, according to the universal definition of AMI in use at the time of the survey 10 • admission within 48 hours of the onset of symptoms • informed consent to participate in the registry.
Patients dying in the first hours following admission, or before blood was drawn, did not require the typical pattern of cardiac markers, provided they had typical symptoms associated with typical ST-T abnormalities, and the diagnosis of AMI was thus considered evident by the investigators. Patients were excluded if their age was <18 years, if symptoms had occurred >48 hours prior to admission, or if the AMI occurred following cardiovascular procedures such as percutaneous coronary interventions or coronary artery bypass graft surgery.
Three patients were excluded from the SWEDEHEART dataset because age was missing (1%), as were 75 patients in whom hospital survival status was missing (64 patients from the MINAP dataset, 8%, and 11 patients from the main survey, 0.3%).
All data were recorded anonymously. Patients gave informed consent for participating in the survey according to the laws applicable in each participating country. Informed consent, however, was not requested for patients dying very early after admission. The protocol was reviewed and approved by ethics committees of the different countries according to national laws applicable.
Data collection
One physician was responsible for collecting the data in each participating centre, and the data were collected on an electronic case record form (CRF) specifically designed by the steering committee members and implemented at the European Heart House. The CRF comprised electronic data controls, generating queries in case of discrepancies in the data entered.
The CRF was used in 45 of the participating countries. In addition, Swedish centres and English and Welsh centres used national CRFs to routinely collect information on patients hospitalized for acute coronary syndromes in the SWEDEHEART 11 and Myocardial Ischaemia National Audit Project (MINAP), 12 respectively. Principal investigators of these registries agreed to extract data collected for patients with ST-segment elevation (STEMI) or non-ST-segment elevation (NSTEMI) during the survey recruitment period, and the data were merged with those from the main snapshot CRF. Because some of the data collected differed between each of the two national registries and the EHS Snapshot database, only those defined in a similar manner were used in the global dataset.
A number of variables collected in the main survey were not collected in the MINAP and/or SWEDEHEART databases (among those: place of arrival, type of hospital, means of transportation to hospital, treatment with nitrates, calcium-channel blockers, diuretics, digoxin, antiarrhythmic agents or oral hypoglycaemic agents before current event, type of presenting symptoms, admission Killip class, arterial access for coronary angiography, in-hospital treatment with loading dose of clopidogrel, glycoprotein IIb/ IIIa inhibitors, fondaparinux, bivalirudin, diuretcis or amiodarone, and complications such as atrial fibrillation, conduction disturbances, stroke, transfusion, or mechanical complications).
Participating centres and countries
Participation was proposed to all institutions in member countries of the ESC, by way of information through the ESC organization (website and mailing lists) and by informing working groups on acute cardiac care in the countries where such groups existed; all participating centres did so on a voluntary basis.
Forty-seven countries participated in the survey, with 465 participating centres in the main survey (70% with percutaneous coronary intervention, PCI, capability on site), 139 additional centres in MINAP (27% with PCI capability on site). and 73 in SWEDEHEART (38% with PCI capability). Most centres (88%) had an intensive cardiac care unit on site.
The participating countries were grouped into five main geographical regions, adapted from the United Nations geoscheme for Europe: 13 
Data recorded
Socio-demographic characteristics comprised age, sex, body mass index, and level of education. Prior medical history and risk factors, as well as medications used regularly for at least 1 month at the time of the infarct, were recorded. Admission characteristics comprised type of AMI (STEMI or NSTEMI), initial symptoms, Killip class on admission, in-hospital medications, and use of invasive procedures.
Statistical analysis
For quantitative variables, means, standard deviations, and minimum and maximum values were calculated. In addition, medians with the interquartile range were calculated for some variables. Discrete variables are presented as percentages. Comparisons were made with chi-squared or Fisher's Exact tests for discrete variables, and by unpaired t-tests, Mann-Whitney tests, Wilcoxon sign-rank tests, or one-way analyses of variance for continuous variables, as appropriate. Odds ratios are given with their 95% confidence intervals. Multivariate analyses of predictors of in-hospital outcome or management were performed by stepwise backward multiple logistic regression analysis, including age, sex, type of MI, and risk factors as covariates. p-values <0.05 were considered significant.
Results
Overall population
Overall, 4236 patients were included in the study: 3198 in the main survey, 732 in MINAP, and 306 in SWEDEHEART.
The mean age of the population was 66±13 years, with 16% aged 80 years or more; 31% were women. The risk factors and previous history are described in Table 1 .
Chest pain was the most common presenting symptom. Half of the patients had used an emergency call number, but most, however, were first admitted to the emergency room; 56% were initially admitted to hospitals with PCI capability.
Overall, 69% had a coronary angiography during the hospital stay and 55% underwent a PCI ( Table 2 ). The inhospital death rate was 6.3%. Antithrombotic treatment, other major medications used in hospital, and other complications are displayed in Table 2 .
Presentation, management, and outcomes according to type of AMI
Sixty per cent of the patients presented with STEMI or presumed new left bundle branch block, with 39% located in the anterior territory. The main characteristics of the patients according to type of MI are presented in Table 1 . Compared with NSTEMI, STEMI patients were younger, more often men, had less diabetes, hypertension, or hyperlipidaemia, but were more often current smokers. Prior medical cardiovascular and noncardiovascular history was less common in STEMI patients, and accordingly they received fewer cardiovascular medications before the index event. At presentation, cardiac arrest and cardiogenic shock were more frequent in STEMI patients.
In STEMI patients, median time from symptom onset to first call was 105 minutes (Table 2) , and 9% were directly brought to the catheterization laboratory.
Primary PCI was the most frequently used reperfusion strategy (50%); 29% of STEMI patients did not get reperfusion therapy ( Table 2) . Median time from qualifying ECG to lysis was 47 minutes, with less than 25% of the patients having lytic treatment within 20 minutes of ECG; median time from ECG to primary PCI was 115 minutes. Time from symptom onset to first call was considerably longer in patients who did not get reperfusion therapy (median time: 250 min vs. 75 min for patients with reperfusion therapy). Reperfusion therapy was used in 77% of patients with first medical contact ≤12 hours from symptom onset (primary PCI 53% and fibrinolysis 24%). By multivariate analysis, time to first call >12 hours (OR 7.17, 95% CI 5.24-9.81), age ≥75 years (OR 1.71, 95% CI 1.22-2.39), history of previous MI (OR 3.29, 95% CI 2.26-4.80), and history of hypertension (OR 1.37, 95% CI 1.06-1.77) were independent correlates of lack of reperfusion therapy, while admission to centres with catheterization laboratories (OR 0.38, 95% CI 0.30-0.49), history of previous PCI (OR 0.31, 95% CI 0.18-0.52), and current smoking (OR 0.66, 95% CI 0.50-0.87) were associated with a lower risk of not getting reperfusion therapy.
There were no significant differences regarding the early use of oral antiplatelet agents, angiotensin-converting enzyme (ACE) inhibitors, statins, or beta-blockers. Higher loading doses of clopidogrel were used in STEMI patients, and more received glycoprotein IIb/IIIa inhibitors, while fewer were treated with low-molecular-weight heparin or fondaparinux.
Guideline-recommended secondary prevention medications at discharge (aspirin, clopidogrel, statins, betablockers, ACE inhibitors) were more often prescribed in STEMI patients; the differences remained statistically significant after multivariate adjustment.
STEMI patients had more frequent in-hospital complications, including death (STEMI 7.9% vs. NSTEMI 3.9%; Table 2 ).
Presentation, management, and outcomes according to main geographical regions
There were important differences in baseline characteristics according to main regions (Table 3 ). Patients in Northern countries were older, and those in Central, Eastern, or Mediterranean countries younger, with a 5-year mean age difference between Northern and Central European countries. The proportion of STEMI was the highest in Eastern countries (74%) and the lowest in Northern countries (46%), with a similar age pattern for STEMI and NSTEMI patients across regions. Patients in Northern countries were more often admitted to non-PCI hospitals, while admission to PCI hospitals was the highest in Western countries.
Median time from symptom onset to call in STEMI patients was longer in Eastern and Western countries than in other regions, with a higher proportion of patients calling beyond 12 hours from onset (24 and 19%, respectively, compared with 12% on average in other regions). The highest use of primary PCI for STEMI was found in Western countries (70%) and the lowest in Eastern countries (23%); (16) [1220] 308 (25) 150 (24) 161 (23) 251 (22) 0.001
Prior PCI 91 (18) [1213] 150 (12) 89 (14) 24 (3.5) 195 (17) <0.001
Prior CABG 28 (6) [1215] 95 (8)
(3.5)
9 (1) 60 (5) <0.001
Prior stroke 21 (4) [1207] 84 (7) 53 (8) 72 (10) 69 (6) 0.002 PAD 33 (7) [899] 40 (4) 43 (7) 25 (4) 71 (6) 0.021
Hx of CHF 26 (5) [1205] 86 (7) 53 (8) 129 (19) 67 (6) <0.001 CKD 41 (8) [906] 44 (5) 38 (6) 40 (6) 101 (9) 0.002 COPD 21 (4) [900] 106 (12) 36 (6) 55 (8) 103 (9) <0.001
Cancer 37 (8) [233] 15 (6) 23 (4) 11 (2) 45 (4) <0.001
Medications before index AMI Aspirin Amiodarone 51 (10) [233) 19 (8) 72 (11) 99 (14) 121 (11) 0.053 (Table 3) . At discharge, there was no difference regarding aspirin and statin prescription; unadjusted rates of clopidogrel, beta-blockers, and ACE inhibitors differed. After multivariate adjustment, clopidogrel was prescribed more often in Northern compared with Western countries (adjusted OR 1.82, 95% CI 1.35-2.47) and less often in Eastern countries (OR 0.53, 95% CI 0.39-0.71); beta-blockers were less often used in Mediterranean (OR 0.70, 95% CI 0.51-0.95), and Northern countries (OR 0.70, 95% CI 0.50-0.99). ACE inhibitors were more often prescribed in Central (OR 1.54, 95% CI 1.17-2.03) and Eastern (OR 1.48, 95% CI 1.13-1.94) countries, compared with Northern countries. There were no significant differences for statin prescription at discharge.
Discharge medications Aspirin
In-hospital death was lowest in Northern countries and highest in Eastern and Central European countries, both in the overall patient population and in STEMI patients. Compared with Western countries, the adjusted OR was 1.66 (95% CI 1.01-2.74; p=0.047) for Central European countries and 2.13 (95% CI 1.32-3.43; p=0.002) for Eastern countries. The statistical significance disappeared, however, when use of PCI was added to the model both for Eastern (OR 1.54, 95% CI 0.93-2.53) and Central European countries (OR 1.55, 95% CI 0.93-2.56). Major bleeding was not significantly different across regions, but transfusions were used less often in Eastern and more often in Northern countries. The occurrence of cardiogenic shock was not significantly different across regions. There were differences in baseline characteristics, type of MI, use of reperfusion therapy in STEMI, and in-hospital mortality among individual countries, but the number of patients included per country was too small to draw firm conclusions in this regard ( Supplementary Figures S1 and S2 , available online).
Discussion
This study provides a global overview of the characteristics, management, and outcomes of patients admitted for [7] [8] [9] It gives information on the type of population admitted to hospitals for AMI, and shows differences in presentation, invasive and medical management, and in-hospital outcomes according to the main geographical regions. STEMI represented the majority of AMI patients admitted to intensive cardiac care units/cardiology departments at the participating centres, with variations across regions which might represent differences in practice regarding admission to intensive care units of NSTEMI patients, rather than true regional differences in the incidence of STEMI vs. NSTEMI. In line with many previous surveys and registries, patients with NSTEMI were older and with more comorbidity. Their in-hospital mortality, however, was lower than that of STEMI patients, as was the occurrence of stroke, cardiogenic shock, and rhythm disturbances. These results are in keeping with most data worldwide.
The survey results also represent a first attempt at assessing the global picture of patients hospitalized for AMI, comparing regional differences in presentation, management and outcomes within member countries of the ESC. There were substantial regional differences in terms of patient profile; in particular, patients from Central or Eastern countries were notably younger than patients in Northern countries. Such differences reflect data reported from national registries published in the 2000s, [14] [15] [16] [17] [18] as well as from administrative databases. 19 Likewise, patient management was significantly different across regions. In STEMI patients, the use of primary PCI, as well as that of reperfusion therapy, was less in Eastern countries, but high in Western and Central European countries; the same trend was noted in National reports, 18 and in the recent Stent for Life ESC survey on primary PCI, where several countries such as the Czech Republic, Poland, or Slovenia had high rates of primary PCI. 20 Primary PCI represented the first reperfusion method in all regions except Eastern countries, where fibrinolysis was used more often. Interestingly, the rate of use of primary PCI and intravenous fibrinolysis in Eastern countries at the end of 2009 was quite similar to the rates observed in Western countries just a few years earlier. 21 The relatively low rate of primary PCI in Northern countries (51%) was largely driven by the practice in England and Wales at the time, where fibrinolytic treatment was still largely used, consistent with the figures reported in the 2009 MINAP report; 22 in contrast, primary PCI was used in 61% of Swedish patients as early as 2006-2007. 23 The use of guideline-recommended medications at discharge was high in all regions: aspirin in 91-94%, clopidogrel, ACE inhibitors, and beta-blockers in about or over 80% of the patients, and statins in 91% of the patients.
In-hospital complications were not frequent. Recurrent myocardial infarction ranged from 1.5 to 4.4%, cardiogenic shock from 5.0 to 7.7%, and major bleeding was reported in 1.2 to 2.1% of patients. In-hospital mortality ranged from 4.1% (Northern countries) to 10.1% (Eastern countries). Interestingly, early mortality in Central and Eastern European countries was comparable to what was found in Western/Northern countries in the early or mid-2000s. Thus, in the French USIC 2000 registry, carried out in November 2000, in-hospital mortality was 8.7%, 16 and it decreased to 5.4% in the FAST-MI 2005 registry 24 and 4.4% in the FAST-MI 2010 registry; 25, 26 in the SWEDEHEART RIKS-HIA registry, in-hospital mortality was also 8.7% in 2000, and was still 7.2% in 2004, to reach a low 5.1% in 2007; 23 in the SWISS registry, in-hospital death rate was 7.6% in 2000 and decreased to 6% in 2007. 27 Overall, there were no gross inequalities in management and outcomes among ESC member countries; we observed a less than 10-year gap for the use of invasive strategies and early mortality between European regions, with a nearly uniform use of recommended medications at discharge.
This study has several limitations that must be taken into consideration when interpreting its results. The most important pertains to its voluntary nature. Although participation was considerably higher than in all previous European surveys, only a minority of the centres providing care for AMI patients actually took part in the survey, thereby limiting the ability of the survey to provide definitive representative figures of the current landscape of AMI management in Europe. A majority of the centres participating in the survey were university hospitals or hospitals with catheterization laboratories on site, which does reflect a lower participation of non-university or smaller hospitals in the survey; even after accounting for patients transferred to larger hospitals, less than half of the patients in the survey were initially admitted to hospitals without PCI capability, a most likely underestimate of their true proportion. Also, participation in some countries was low, so that comparisons between countries should be taken with extreme care and should not be considered more than purely indicative. In addition, because of the short duration of the inclusion period, the number of patients included in any given country remains relatively small, and therefore limit the ability to perform country-wise comparisons. The results of the survey, however, are in line with most national or regional contemporary surveys. Conversely, the short duration of the study makes it more likely that patient inclusion at the participating centres was truly consecutive. Finally, the source of the data came from both a specific case record form, designed for the snapshot survey, and from extractions from national databases (MINAP and SWEDEHEART) for the survey inclusion period; as the structure of the three databases differed, some variables were not available for all patients, and therefore limit the potential for some comparisons between Northern countries and the other participating countries.
In conclusion, overall, this survey provides a global picture of AMI presentation, management and outcomes in Europe at the end of 2009. Differences continue to exist between regions, in terms of patient populations and management, but these differences are relatively modest and are likely to rapidly attenuate further with the growing use of invasive strategies and reperfusion therapy for STEMI patients. One of the key determinants of improved outcomes, particularly for the STEMI population, is the implementation of regional networks, which is now strongly advocated in the most recent ESC guidelines. 4 In addition, implementing regional, national or international surveys of practice is likely to further improve quality of care for this acute cardiac condition.
